Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Novo and Lilly just slashed prices on GLP-1 weight-loss drugs that recently cost over $1,000 a month. What happened?

Novo Nordisk shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...

Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in ...

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...

The results from the two trials of early-stage Alzheimer's patients, called EVOKE and EVOKE+, are another setback for the ...

Overindulging in rich foods while taking a drug like Wegovy or Zepbound can raise the risk of side effects like nausea and ...